Moderna Says Omicron Booster Could Be Ready By March, But Fauci Says Not To Wait

TOPLINE

Moderna President Stephen Hoge said Wednesday Covid-19 booster shots targeting the omicron variant could be ready to present for U.S. authorization by March, though both he and federal infectious disease point man Dr. Anthony Fauci said they believe current vaccines will be effective against the new strain, with Fauci advising the public to get a booster now. 

KEY FACTS

Moderna has begun to develop an omicron-specific booster, Hoge told Reuters, as well as a multi-valent vaccine targeting omicron and three other coronavirus variants, though that shot will take several more months. 

The March target date is the earliest the omicron booster could be approved under the U.S. Food and Drug Administration’s current guidelines, though the company would manufacture the vaccine during testing.

Hoge said he thinks the existing vaccines “will be able to slow down, if not completely stop, the omicron variant.”

Fauci advised the public in a press conference Wednesday morning to “get boosted now,” as “we may not need a variant-specific boost,” though he said the Biden administration has been in contact with the pharmaceutical companies developing Covid-19 vaccines about the potential need for these boosters.

CRUCIAL QUOTE

“Our experience with variants such as the delta variant is that even though the vaccine isn’t specifically targeted to the delta variant, when you get a high enough level of an immune response, you get spillover protection even against a variant that the vaccine wasn’t specifically directed at,” Fauci said Wednesday.

KEY BACKGROUND

The first documented U.S. case of the omicron variant was reported in San Francisco on Wednesday. The individual, who recently returned from a trip to South Africa where the variant was first identified, was vaccinated for Covid-19 but had not received a booster. They are currently experiencing mild symptoms. Fauci said Wednesday it is too early to tell whether the omicron variant is more deadly than the delta variant.

TANGENT

Pfizer and BioNTech are conducting clinical trials for an updated version of their vaccine that would target the full spike protein of the delta variant.

By Mason Bissada, Forbes Staff